Scholarlink

<p>Contemporary management of multiple sclerosis is based on the clinical course descriptors of relapsing–remitting, secondary progressive and primary progressive. However, recognition is growing in the field that these clinical course descriptors do not capture the full disease spectrum of multiple sclerosis or reflect the underlying biological mechanisms of disease, and that biologically informed course descriptors are needed. In this Roadmap, participants in an International Advisory Committee on Clinical Trials in Multiple Sclerosis workshop discuss the problems with the existing course descriptors, highlight considerations for developing new course descriptors and propose a roadmap for transitioning towards a more dynamic, biologically informed description of the&#xa0;multiple sclerosis disease course.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Towards a biologically informed description of multiple sclerosis disease course — a roadmap for transition

  • 期刊论文

  • 发表日期：

    2026年8月3日

查看全文
  • Alan J. Thompson,
  • Fred D. Lublin,
  • Lindsay Rechtman,
  • James Quinn,
  • Maria Pia Amato,
  • Bruce Bebo,
  • Peter A. Calabresi,
  • Julie Fiol,
  • Marcia Finlayson,
  • Annie Hawton,
  • Tanja Kuhlmann,
  • Ruth Ann Marrie,
  • Marcello Moccia,
  • Xavier Montalban,
  • Michael Panzara,
  • Kathy Smith,
  • Maria Pia Sormani,
  • Jon Strum,
  • Barbara G. Vickrey,
  • Timothy Coetzee,
  • Lilyana Amezcua,
  • Brenda Banwell,
  • Frederik Barkhof,
  • Amit Bar-Or,
  • Helmut Butzkueven,
  • Jeremy Chataway,
  • Olga Ciccarelli,
  • Jorge Correale,
  • Kazuo Fujihara,
  • Cristina Granziera,
  • Kerstin Hellwig,
  • Joep Killestein,
  • Dorlan Kimbrough,
  • Daphne Kos,
  • Christine Lebrun-Frénay,
  • Aaron Miller,
  • Jiwon Oh,
  • Daniel Ontaneda,
  • Sudarshini Ramanathan,
  • Daniel Reich,
  • Mara Rocca,
  • Amber Salter,
  • Andrew Solomon,
  • Bruno Stankoff,
  • Mar Tintoré,
  • Helen Tremlett,
  • Anneke van der Walt,
  • Paola Zaratin

摘要

Contemporary management of multiple sclerosis is based on the clinical course descriptors of relapsing–remitting, secondary progressive and primary progressive. However, recognition is growing in the field that these clinical course descriptors do not capture the full disease spectrum of multiple sclerosis or reflect the underlying biological mechanisms of disease, and that biologically informed course descriptors are needed. In this Roadmap, participants in an International Advisory Committee on Clinical Trials in Multiple Sclerosis workshop discuss the problems with the existing course descriptors, highlight considerations for developing new course descriptors and propose a roadmap for transitioning towards a more dynamic, biologically informed description of the multiple sclerosis disease course.